Publication
Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (5)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 5
- drugPalbociclibcivic_curation1.00
- geneCCNE1civic_curation1.00
- geneRB1civic_curation1.00
- variantCCNE1 Amplificationcivic_curation1.00
- variantRB1 M695FS*26civic_curation1.00
Curated evidence
Evidence citing this paper (2)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 27020857
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| CCNE1 Amplification1 | ||||||||
| Palbociclib | Estrogen Receptor-positive Breast CancerUNRESOLVED | Predictive | D | Supports Resistance | 3 | accepted | EID1629Preclinical study in breast cancer cell lines treated with CDK4/6 inhibitor palbociclib. Cell lines with acquired resistance to palbociclib were developed. Two palbociclib-resistant cell lines were de… (full text at CIViC) PMID 27020857 · Herrera-Abreu et al., 2016 · Open in CIViC | civic |
| RB1 M695FS*261 | ||||||||
| Palbociclib | Estrogen Receptor-positive Breast CancerUNRESOLVED | Predictive | D | Supports Resistance | 2 | accepted | EID1630Preclinical study in breast cancer cell lines treated with CDK4/6 inhibitor palbociclib. Palbociclib-resistant xenografts from one cell line (PDX244) were developed in-vivo. In resistant xenografts, w… (full text at CIViC) PMID 27020857 · Herrera-Abreu et al., 2016 · Open in CIViC | civic |